POM-V Prescription Required Companion Animal

Robexera 6 mg Chewable Tablets for Cats

Active ingredient: Robenacoxib

Form

Chewable

Species

Cats

Manufacturer

KRKA, d.d., Novo mesto

VMD MA No.

01656/5121

What it's used for

For the reduction of moderate pain and inflammation associated with orthopaedic surgery in cats.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Robenacoxib

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Robexera 6 mg Chewable Tablets for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the reduction of moderate pain and inflammation associated with orthopaedic
surgery in cats.

Give either without food or with a small amount of food. The tablets should not be
divided or broken.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2.4
mg/kg. The following number of tablets should be given once daily at the same time
every day:
Body weight
(kg)
Number of
tablets
2.5 to < 61 tablet6 to 122 tablets
Acute musculoskeletal disorders: treat for up to 6 days.
Chronic musculoskeletal disorders: Duration of treatment should be decided on
an individual basis. Please refer to section 3.5.
A clinical response is normally seen within 3-6 weeks. Treatment should be
discontinued after 6 weeks if no clinical improvement is apparent.
Orthopaedic surgery: Give as a single oral treatment prior to orthopaedic surgery.
Premedication should only be carried out in combination with butorphanol-analgesia.
The tablet(s) should be administered without food at least 30 minutes prior to
surgery.
After surgery, once daily treatment may be continued for up to two further days. If
necessary, additional analgesic treatment with opioids is recommended.
The interchangeable use of veterinary medicinal product in the form of tablets and
solution for injection has been tested in a target animal safety study and was shown
to be well tolerated by cats.
For cats, Robexera solution for injection or tablets may be used interchangeably in
accordance with the indications and directions of use approved for each
pharmaceutical form. Treatment should not exceed one dose (either tablet or
injection) per day. Please note that the recommended doses for the two formulations
are different.

Do not use in cats suffering from gastrointestinal ulceration.
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory
drugs (NSAIDs).
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in pregnant and lactating animals (see section 3.7).

Cats:
Common
(1 to 10 animals / 100 animals
treated):
Diarrhoea
, Vomiting
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Elevated renal parameters (creatinine, BUN, and
SDMA)
Renal insufficiency
Lethargy
Mild and transient.
More commonly in older cats and with concomitant use of anaesthetic or sedative
agents.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in cats
weighing less than 2.5 kg or under 4 months of age.
Use in cats with impaired cardiac, renal or hepatic function or in cats that are
dehydrated, hypovolaemic or hypotensive may involve additional risks. If use cannot
be avoided, these cats require careful monitoring.
Response to treatment should be monitored at regular intervals by a veterinary
surgeon. Clinical field studies showed that robenacoxib was well-tolerated by most
cats for up to 12 weeks.
Use this veterinary medicinal product under strict veterinary monitoring in cats with a
risk of gastrointestinal ulcers, or if the cat previously displayed intolerance to other
NSAIDs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In pregnant women, particularly near-term pregnant women, prolonged dermal
exposure increases the risk for premature closure of the ductus arteriosus in the
foetus. Pregnant women should take special care to avoid accidental exposure.
In small children, accidental ingestion increases the risk for NSAID adverse effects.
Care should be taken to avoid accidental ingestion by children. In order to prevent
children from accessing the product, do not remove tablets from the blister until ready
to administer to the animal. Tablets should be administered and stored (in the
original packaging) out of sight and reach of children. In case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to the
physician.
Wash hands after use of the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.

This veterinary medicinal product must not be administered in conjunction with other
NSAIDs or glucocorticosteroids. Pre-treatment with other anti-inflammatory
medicines may result in additional or increased adverse effects and, accordingly, a
treatment-free period with such substances should be observed for at least 24 hours
before the commencement of treatment with this veterinary medicinal product. The
treatment-free period, however, should take into account the pharmacokinetic
properties of the products used previously.
Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics
or angiotensinconverting enzyme (ACE) inhibitors, should be subject to clinical
monitoring. In healthy cats treated with or without the diuretic furosemide,
concomitant administration of this veterinary medicinal product with the ACE inhibitor
benazepril for 7 days was not associated with any negative effects on plasma
aldosterone concentrations, plasma renin activity or glomerular filtration rate. No
safety data in the target population and no efficacy data in general exist for the
combined treatment of robenacoxib and benazepril.
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy during
surgery should be considered to decrease potential renal complications when using
NSAIDs peri-operatively.
Concurrent administration of potentially nephrotoxic medicines should be avoided as
there might be an increased risk of renal toxicity.
Concurrent use of other active substances that have a high degree of protein binding
may compete with robenacoxib for binding and thus lead to toxic effects.

Do not store above 30 °C. Store in the original package in order to protect from
moisture.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.